Galectin Therapeutics (GALT) Preferred Dividend Payments (2010 - 2026)
Galectin Therapeutics' quarterly Preferred Dividend Payments came in at $21000.0 in Q1 2026, up 180.77% year-on-year from $7479.5 in Q1 2025, and down 66.13% quarter-over-quarter from $62000.0 in Q4 2025.
Galectin Therapeutics has reported Preferred Dividend Payments for 17 years, with the latest figure at $21000.0 in Q1 2026.
- For the quarter ending Q1 2026, Preferred Dividend Payments rose 180.77% year-over-year to $21000.0; the trailing twelve-month figure through Mar 2026 stood at $185000.0 (up 55.46% YoY), and the FY2025 full-year result was $138000.0, down 9.8% from the prior year.
- Preferred Dividend Payments for Q1 2026 stood at $21000.0, down from $62000.0 in the prior quarter.
- The five-year high for Preferred Dividend Payments was $65000.0 in Q4 2022, with the low at -$26000.0 in Q1 2025.
- Average Preferred Dividend Payments over 5 years is $33062.5, with a median of $50500.0 recorded in 2025.
- Year-over-year, Preferred Dividend Payments tumbled 900.0% in 2022 and surged 400.0% in 2024.
- Tracing GALT's Preferred Dividend Payments over 5 years: stood at $65000.0 in 2022, then declined by 3.08% to $63000.0 in 2023, then changed by 0.0% to $63000.0 in 2024, then declined by 1.59% to $62000.0 in 2025, then sank by 66.13% to $21000.0 in 2026.
- The last three Preferred Dividend Payments figures came in at $21000.0 (Q1 2026), $62000.0 (Q4 2025), and $39000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Mar 31, 2025 | -26,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Sep 30, 2023 | -6,000.00 |
| Jun 30, 2023 | 63,000.00 |
| Dec 31, 2022 | 65,000.00 |
| Sep 30, 2022 | -16,000.00 |
| Jun 30, 2022 | 64,000.00 |
| Mar 31, 2022 | -16,000.00 |
| Dec 31, 2021 | 67,000.00 |
| Sep 30, 2021 | 37,000.00 |
| Jun 30, 2021 | 65,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | 65,000.00 |
| Sep 30, 2020 | 12,000.00 |
| Jun 30, 2020 | 66,000.00 |
| Mar 31, 2020 | -6,000.00 |
| Dec 31, 2019 | 65,000.00 |
| Sep 30, 2019 | 35,000.00 |
| Jun 30, 2019 | 67,000.00 |
| Mar 31, 2019 | 96,000.00 |
| Dec 31, 2018 | 299,000.00 |
| Sep 30, 2018 | 294,000.00 |
| Jun 30, 2018 | 268,000.00 |
| Mar 31, 2018 | 285,000.00 |
| Dec 31, 2017 | 405,000.00 |
| Sep 30, 2017 | 254,000.00 |
| Jun 30, 2017 | 301,000.00 |
| Mar 31, 2017 | 272,000.00 |
| Dec 31, 2016 | -365,000.00 |
| Sep 30, 2016 | 63,000.00 |
| Jun 30, 2016 | 250,000.00 |
| Mar 31, 2016 | 153,000.00 |
| Dec 31, 2015 | -400,000.00 |
| Sep 30, 2015 | 57,000.00 |
| Jun 30, 2015 | 58,000.00 |
| Mar 31, 2015 | 57,000.00 |
| Dec 31, 2014 | 180,000.00 |
| Sep 30, 2014 | 278,000.00 |
| Jun 30, 2014 | 57,000.00 |
| Mar 31, 2014 | 58,000.00 |
| Dec 31, 2013 | 696,000.00 |
| Sep 30, 2013 | 123,000.00 |
| Jun 30, 2013 | 57,000.00 |
| Mar 31, 2013 | 213,000.00 |
| Dec 31, 2012 | 58,000.00 |
| Sep 30, 2012 | 58,000.00 |
| Jun 30, 2012 | 267,000.00 |
| Mar 31, 2012 | 57,000.00 |
| Dec 31, 2011 | -73,000.00 |
| Sep 30, 2011 | 58,000.00 |
| Jun 30, 2011 | 750,000.00 |
| Mar 31, 2011 | 58,000.00 |
| Dec 31, 2010 | 238,000.00 |
| Sep 30, 2010 | 239,000.00 |
| Jun 30, 2010 | 227,000.00 |